Jouni Tuisku Selected Research

Multiple Sclerosis

2/2022	Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET.
12/2020	Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
10/2017	Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
6/2014	In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jouni Tuisku Research Topics

Disease

7	Inflammation (Inflammations) 01/2023 - 09/2013
4	Parkinson Disease (Parkinson's Disease) 01/2024 - 01/2021
4	Neuroinflammatory Diseases 01/2023 - 01/2020
4	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2020
4	Multiple Sclerosis 02/2022 - 06/2014
2	Gambling (Pathological Gambling) 01/2024 - 01/2019
2	Insulin Resistance 12/2023 - 01/2023
1	Overweight 01/2024
1	Schizophrenia (Dementia Praecox) 01/2024
1	Hyperinsulinism (Hyperinsulinemia) 10/2023
1	Obesity 10/2023
1	Morbid Obesity 10/2023
1	Weight Loss (Weight Reduction) 10/2023
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023
1	Dyskinesias (Dyskinesia) 01/2023
1	Dementia (Dementias) 01/2021
1	Psychotic Disorders (Schizoaffective Disorder) 01/2020
1	Cognitive Dysfunction 01/2020
1	Mental Disorders (Mental Disorder) 01/2020
1	Alcoholism (Alcohol Abuse) 01/2019
1	Opiate Overdose 01/2019
1	Pathologic Processes 09/2016
1	Psoriatic Arthritis 09/2016
1	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2016
1	Encephalitis (Encephalitis, Rasmussen) 06/2014
1	Chronic Progressive Multiple Sclerosis 09/2013

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 02/2022 - 06/2014
4	Amyloid beta-PeptidesIBA 12/2023 - 01/2022
4	Apolipoproteins E (ApoE)IBA 12/2023 - 01/2021
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 06/2014
3	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2023 - 09/2013
2	C-Reactive ProteinIBA 01/2023 - 01/2021
2	KF18446IBA 01/2023 - 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 01/2024
1	RacloprideIBA 01/2024
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2024
1	N-acetylaspartate (N-acetyl aspartate)IBA 10/2023
1	CreatineIBA 10/2023
1	Glucose (Dextrose)FDA LinkGeneric 10/2023
1	Inositol (Myoinositol)IBA 10/2023
1	Insulin (Novolin)FDA Link 10/2023
1	CholesterolIBA 01/2023
1	(R)- (11C)1- (2- chlorophenyl)- N- methyl- N- (1- methylpropyl)- 3- isoquinolinecarboxamideIBA 01/2023
1	Apolipoprotein E4IBA 01/2023
1	Adenosine (Adenocard)FDA LinkGeneric 01/2021
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 01/2021
1	carfentanil (carfentanyl)IBA 01/2020
1	Chemokine CCL22IBA 01/2020
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2020
1	ChemokinesIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	Naloxone (Narcan)FDA LinkGeneric 01/2019
1	Nasal SpraysIBA 01/2019
1	Opioid Receptors (Opioid Receptor)IBA 01/2019
1	Natalizumab (Tysabri)FDA Link 01/2019
1	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2019
1	Fingolimod Hydrochloride (FTY720)FDA Link 10/2017
1	Fluorine-18IBA 09/2016
1	MannansIBA 09/2016
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2015
1	LigandsIBA 06/2014